Efavirenz-associated CNS disorders linked to CYP2B6 variant

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2005年 / 1035卷 / 1期
关键词：
Central Nervous System; Randomise Control Trial; Haas; Efavirenz; Trial Group;
D O I：
10.2165/00128415-200510350-00009
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5 / 5
相关论文
共 50 条
  • [41] THE IMPACT OF CYP2B6 GENOTYPE ON EFAVIRENZ AUTO-INDUCTION: PHARMACOKINETICS MODEL AND SIMULATION
    Li, L.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S55 - S55
  • [42] The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy
    Zakaria, Zaril
    Badhan, Raj K. S.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 119 : 90 - 101
  • [43] Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
    Carr, Daniel F.
    la Porte, Charles J. L.
    Pirmohamed, Munir
    Owen, Andrew
    Cortes, Claudia P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) : 1889 - 1893
  • [44] Methadone N-Demethylation by the Common CYP2B6 Allelic Variant CYP2B6.6
    Gadel, Sarah
    Crafford, Amanda
    Regina, Karen
    Kharasch, Evan D.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (04) : 709 - 713
  • [45] High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
    Nyakutira, Christopher
    Roshammar, Daniel
    Chigutsa, Emmanuel
    Chonzi, Prosper
    Ashton, Michael
    Nhachi, Charles
    Masimirembwa, Collen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) : 357 - 365
  • [46] High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
    Christopher Nyakutira
    Daniel Röshammar
    Emmanuel Chigutsa
    Prosper Chonzi
    Michael Ashton
    Charles Nhachi
    Collen Masimirembwa
    European Journal of Clinical Pharmacology, 2008, 64 : 357 - 365
  • [47] PharmVar GeneFocus: CYP2B6
    Desta, Zeruesenay
    El-Boraie, Ahmed
    Gong, Li
    Somogyi, Andrew A.
    Lauschke, Volker M.
    Dandara, Collet
    Klein, Kathrin
    Miller, Neil A.
    Klein, Teri E.
    Tyndale, Rachel F.
    Whirl-Carrillo, Michelle
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 82 - 97
  • [48] Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations
    Ayuso, Pedro
    Neary, Megan
    Chiong, Justin
    Owen, Andrew
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) : 3281 - 3290
  • [49] CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
    Metzger, Ingrid F.
    Dave, Nimita
    Kreutz, Yvonne
    Lu, Jessica B. L.
    Galinsky, Raymond E.
    Desta, Zeruesenay
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, : 657 - 666
  • [50] Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
    Hui, K. H.
    Lee, S. S.
    Lam, T. N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (04): : 182 - 191
12345